Outcomes from a randomized, double-blind, placebo-controlled trial of monthly injectable buprenorphine for methamphetamine use disorder: CTN-0110.
Stimulants are the drivers of the fourth wave of the United States drug overdose epidemic. Kappa opioid receptor antagonists promote feelings of wellbeing and represent a medication addressing the “dark side.” In a pilot study, extended-release naltrexone (XR-NTX) plus oral buprenorphine (BUP), 4mg and 16mg, produced modest, though statistically significant, reductions in cocaine use among those adherent to oral BUP compared to placebo. This presentation describes CTN-0110, a study designed to test monotherapy for buprenorphine as the medication is used for treatment of refractory depression in people with no opioid use disorder (OUD).
Related protocols: CTN-0110
Categories:
Buprenorphine, Cocaine, Naltrexone, Stimulant use
Authors:
Shoptaw, Steven J.; Ghitza, Udi E.; Nieto, Steven; Anderson, Erik; Chowdhury, Tara; Croff, Julie; Hall, Timothy; Tsui, Judith I.; Carmody, Thomas; Wakhlu, Sidarth; Jha, Manish Kumar; Kalmin, Mariah; Trivedi, Madhukar H.
Source:
Presented at the College on Problems of Drug Dependence (CPDD) annual meeting, 2024